everyone, update fourth of corporate Good call and our to Sarah. quarter you, XXXX. for the morning, Thank welcome financial and
Brian your available is and rest of with DeSchuytner, be Finance our The Senior prepared the Product Joining for remarks Strategy. questions. will me today of team VP management
with the and our a in great data in accomplishments ADC and rich yet to utilizing our and platforms deal XXXX XXXX. our have laid first-in-class DolaLock undisclosed including two made pipeline and early-stage Our ADC, on platform in driven plans foundation STING development target. a for XXXX, of for advance BX-HX candidates innovative headway agonist as and Immunosynthen advancing ADC We for based XXXX milestone XXXX
year; for stages to outline our last going I’ll of remainder provide the for programs Brian year corporate full an will just the provide financial early-stage a our the provided Francisco. in San of month and we overview and clinical and goals remarks prepared We're of brief, comprehensive quarter because the XXXX. then, milestones update and our our and fourth keep results
Dolaflexin and I'll with wholly-owned XXXX, start first-in-class NaPiXb. ADC, targeting our
expansion As progress the Since at confirmed very stable and made track establish putting proof-of-concept disclosed safety have doses to in disease XXXX, significant ASCO patients. we at in initiated then, unselected us prolonged we at responses higher cohorts, doses and biomarker in in XMT-XXXX heavily-pretreated activity has and and demonstrating well-tolerated XXXX. shown on
without with More other Grade and we primarily X platforms. X with and and cleared dose squared neuropathy XX events, level adverse toxicity seen specifically, milligrams ocular per the meter have and Grade severe XX ADC the neutropenia
milligram maximum-tolerated squared a dose per are the dose. We and have not XX meter currently evaluating yet determined
March Society at XXth. that the of an dose upcoming was learned our Toronto late-breaker of escalation data updated or presentation accepted our cancer recently SGO, annual we in Oncology on Gynecologic Phase Importantly, meeting X for women's abstract oral on
squared in XX, patients, longer unselected escalation these of early of and There ASCO and are lung dose doses XXXX dose the a patients. and patients This are of also expression. data previously activity per XX presented cancer an at ovarian provide first and are patient disclosed encouraging treated profile other at update the will follow-up The escalation had low patients cell XX data tolerability the patients XMT-XXXX meter SGO signs including XX total ASCO presented non-small will generally ongoing be characterize NaPiXb were new XX of on tumors very-heavily-pretreated with The cancer and disclosure to cohorts. on include will oral demonstrate biomarker patients. dose that XX at and from of lower presentation XX-milligram study patients levels
By the investigational progressed dose The poor having therapies patients and are a therapy, Multiple therapy. third rapidly the in of of on the Furthermore, just or rate these prognosis approaches have of but studies selected of of very-poor on not the lines with available fourth also for been antigen. line response response patients often the increasing these published expression deteriorating prognosis, not therapies. patients zero. escalation study have likelihood very-heavily-pretreated and demonstrate
be is will longer we to information to of and both safety terms study toxicity as limiting safety escalation in doses well tolerability, the as follow-up. of on focus assess primary able data short-term dose term provide The and
communicated data meter in will evaluating SGO and be complete be As we're squared still we not the the enough to in disclosed have before, XX per presentation. time milligrams
show to We continue activity disease. to confirmed see stable and responses further prolonged plan and
H-score. impacted degree measured by by appreciate, of As of dose, and activities line NaPiXb expression therapy is you will
dose, we and cutoff be preliminary a data able selection. will premature to the it each limited H-score to is patients will and showing for patient While share establish number in be subgroup activity, of
held the X:XX from are live conference data The will the SGO, disclosures session We're We to planning XXth late-breaking a to host webcast scheduled data closes that and the day. to three be in of presentation in after XXXX. at that this presenting planning March XMT-XXXX Time. X:XX Eastern is same call market excited first on be oral we’re
get further We the to with date. we provide the as webcast the and details will information dial-in closer
Now, moving the onto expansion cohorts.
XX milligrams the meter per is adopted. to on our rapidly amendment dose We track. to And are in being protocol the recruitment squared move
they're are Although the study. in expansion the still late-stage, than those homogeneous escalation dose patients in the more cohorts
the where to population, study. in we for rate, cohort NaPiXb to a response seek pivotal establish objective proof-of-concept a expression Our the is will and patient including expansion duration cutoff run
In standard-of-care. ovarian single this the we show and X XX% the single-agent of standard-of-care X and a defined fast-to-market above PFS. to response performance X% Within using have rate contemporary chemotherapy response cancer, the rate months study is in cancer, to believe to a setting this have studies a as standard-of-care we ovarian historical registration path arm multiple
medical selection collection in in fresh will In the has this at with and lung expansion need progression NaPiXb unmet archival docetaxel, overall mutations, of both is possibilities tissue of overall. better reported rate XX%, platinum-based to patient cancer, non-small to months. but precedents lung and as an response checkpoint oncogenic to phase the harboring inhibitors non-small There correlation population. X the of patients paths combination tumors fewer The or or The median selection cancer, survival mutations we we expression EGFR XX% triple fast-to-market allow in in progression-free continue of define to with KRAS patient cell intriguing with failure standard-of-care standard-of-care on following for chemotherapy XXXX, of for strategy targeted agents. evaluate targeted high driver raises meeting the the therapy and options. cell us alone further in X for This are
quarter. interim in the will after disclosure expansion SGO Our data dose second be next
data forward the safety the disclosure cohorts, on information more at will and provide well look second patient an very-pleased as the efficacy, The cohorts. mature to year, from expansion second including potential throughout year. from the In more provide XMT-XXXX of We're presenting to at strategy. early advancing the as in on election half the to-date expansion and progress data we look SGO with proof-of-concept the this progress made plan the and towards
bystander turn for DolaLock which in we our developed and enhanced hydrophilicity was our drug-like conjugation, greater our XMT-XXXX, the candidate, and second proprietary I retains added to of clinical with disclosed platform have January. precise payload new tumor effect, drug-to-antibody but auristatin to designed will properties further benefits XMT-XXXX is ratio, even site-specific Dolasynthen. Dolasynthen using exposure. controlled now
for chosen have our target We the as following. first XMT-XXXX, on based NaPiXb
non-small high lung us of penetration. validated goal on large profile, a in shown shot clinically, differentiated fourfold cancer, need. cancer, lung important has medical an provide in we can with this a XXXX cancer, over efficacy tumor very where First, models pre-clinically, unmet second If in a saw particularly XMT-XXXX lung indication consistent significant increase cell with
molecules, validation achieve clinical of the selecting manufactured and commonalities which the antibody are can Dolasynthen the platform is our leadership DolaLock This target validation the the ideal given relationships XMT-XXXX candidates. between we and being and to given also future for decide, efficiently, help two commercial our at NaPiXb, of pipeline our us with investigators will payload a Second, the both patient understanding platform when scale. in population,
already where have potential activity. our for target position ideal an tolerability we're encouraging seeing is a and position. safety, XXXX the further platforms, NapiXb believe leadership are first-in-class we XXXX, with in we our Lastly, ADC extend and we to With
We preclinical in XMT-XXXX specifics as the Stay first the track more dose data study disclosure AACR Phase at get additionally, present in we further to of initiate are meeting. for April. closer on the escalation half to XMT-XXXX plan of we X on to upcoming meeting XXXX tuned this
BX-HX first-in-class advance We're to ADC. continuing our
on suited opportunities. a of we our As payload ADC is of good a this for for our have unique fit the focusing targeted, well and and described, great fast-to-market platforms, characteristics DolaLock strategy potential
ADCs Dolasynthen nonhuman BX-HX, data this in with and we second targeting disclose We development of half expect have primate compelling the our and the efficacy candidate Dolaflexin and preclinical to both supporting data and tolerability year.
targets. continuing efficacy robust to Finally, advance we multiple have discovery across of set pipeline, our Immunosynthen a and data tolerability we're
innate in system game is changer. targeted The potential immune the potential safe to cancer manner of a and activating fight a
ADC finalize preclinical XXXX. and design to half at first disclose from select and We work of excited meeting prioritization annual are track an for development are upcoming We're the our second target platform planning in candidate further to Immunosynthen potential of STING in this AACR and the April. this agonist on platform data the
a have with busy closing, opportunities ahead multiple year value. but build we In of to exciting us
nearing first-in-class needs proof-of-concept, to and targets. resources that would we the robust on have differentiated it’s significant this us ADCs ADC a efficiently pipeline innovative financial designed pipeline for for execute platforms patients, [indiscernible], to cancer generate have to of of growing candidates And We allow lead and a multiple a address unmet plan. medical asset,
on each as progress these forward are excited and of fronts. updating for We year you the look ahead we to
the of that, I President, Finance call our Senior Strategy and to for an Vice financial DeSchuytner, Brian Product over turn with will Mersana’s And results. overview
